Zhengye Biotechnology Holding Limited Financials
This page shows Zhengye Biotechnology Holding Limited (ZYBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a working-capital and depreciation cushion: cash stayed positive while reported earnings and margins collapsed.
The striking disconnect is that FY2025 posted a-$10.0M net loss yet still generated$1.9M of operating cash flow. That cash survival looks temporary rather than operationally strong, because gross margin fell from49.0% to20.5% while receivables and inventory both declined, implying non-cash charges and a working-capital release carried cash flow as earnings weakened.
Overhead stopped fitting the revenue base: FY2025 gross profit was only
The balance sheet still looks lightly levered, with long-term debt of just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Zhengye Biotechnology Holding Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Zhengye Biotechnology Holding Limited has an operating margin of -60.6%, meaning the company retains $-61 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 8.8% the prior year.
Zhengye Biotechnology Holding Limited's revenue declined 34.8% year-over-year, from $25.5M to $16.6M. This contraction results in a growth score of 0/100.
Zhengye Biotechnology Holding Limited carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Zhengye Biotechnology Holding Limited's current ratio of 1.14 is below the typical benchmark, resulting in a score of 18/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Zhengye Biotechnology Holding Limited has a free cash flow margin of 10.6%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.
Zhengye Biotechnology Holding Limited generates a -27.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 4.0% the prior year.
Zhengye Biotechnology Holding Limited passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Zhengye Biotechnology Holding Limited generates $-0.19 in operating cash flow ($1.9M OCF vs -$10.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Zhengye Biotechnology Holding Limited earns $-20.7 in operating income for every $1 of interest expense (-$10.1M vs $486K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Zhengye Biotechnology Holding Limited generated $16.6M in revenue in fiscal year 2025. This represents a decrease of 34.8% from the prior year.
Zhengye Biotechnology Holding Limited's EBITDA was -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 214.7% from the prior year.
Zhengye Biotechnology Holding Limited reported -$10.0M in net income in fiscal year 2025. This represents a decrease of 744.0% from the prior year.
Cash & Balance Sheet
Zhengye Biotechnology Holding Limited generated $1.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 53.0% from the prior year.
Zhengye Biotechnology Holding Limited held $7.2M in cash against $1.4M in long-term debt as of fiscal year 2025.
Zhengye Biotechnology Holding Limited had 47M shares outstanding in fiscal year 2025. This represents an increase of 3.8% from the prior year.
Margins & Returns
Zhengye Biotechnology Holding Limited's gross margin was 20.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 28.5 percentage points from the prior year.
Zhengye Biotechnology Holding Limited's operating margin was -60.6% in fiscal year 2025, reflecting core business profitability. This is down 69.4 percentage points from the prior year.
Zhengye Biotechnology Holding Limited's net profit margin was -60.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 66.1 percentage points from the prior year.
Zhengye Biotechnology Holding Limited's ROE was -27.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 31.9 percentage points from the prior year.
Capital Allocation
Zhengye Biotechnology Holding Limited invested $2.6M in research and development in fiscal year 2025. This represents an increase of 46.9% from the prior year.
Zhengye Biotechnology Holding Limited invested $144K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 92.3% from the prior year.
ZYBT Income Statement
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A |
ZYBT Balance Sheet
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Total Assets | $62.4M-11.4% | $70.4M+4.2% | $67.6M |
| Current Assets | $19.6M-30.1% | $28.1M+15.6% | $24.3M |
| Cash & Equivalents | $7.2M+13.1% | $6.4M+149.7% | $2.5M |
| Inventory | $5.6M-25.1% | $7.5M-6.3% | $8.0M |
| Accounts Receivable | $2.6M-48.7% | $5.2M-36.8% | $8.2M |
| Goodwill | N/A | N/A | N/A |
| Total Liabilities | $18.6M-4.7% | $19.5M+1.0% | $19.3M |
| Current Liabilities | $17.2M-8.5% | $18.8M+1.1% | $18.6M |
| Long-Term Debt | $1.4M+99.7% | $684K+4.0% | $658K |
| Total Equity | $35.7M-14.4% | $41.7M+7.3% | $38.9M |
| Retained Earnings | -$3.1M-183.8% | $3.7M-44.0% | $6.6M |
ZYBT Cash Flow Statement
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A |
ZYBT Financial Ratios
| Metric | Q4'25 | Q2'25 | Q4'24 |
|---|---|---|---|
| Gross Margin | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Current Ratio | 1.14-0.4 | 1.49+0.2 | 1.31 |
| Debt-to-Equity | 0.04+0.0 | 0.020.0 | 0.02 |
| FCF Margin | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Zhengye Biotechnology Holding Limited's annual revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported $16.6M in total revenue for fiscal year 2025. This represents a -34.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zhengye Biotechnology Holding Limited's revenue growing?
Zhengye Biotechnology Holding Limited (ZYBT) revenue declined by 34.8% year-over-year, from $25.5M to $16.6M in fiscal year 2025.
Is Zhengye Biotechnology Holding Limited profitable?
No, Zhengye Biotechnology Holding Limited (ZYBT) reported a net income of -$10.0M in fiscal year 2025, with a net profit margin of -60.0%.
What is Zhengye Biotechnology Holding Limited's EBITDA?
Zhengye Biotechnology Holding Limited (ZYBT) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Zhengye Biotechnology Holding Limited have?
As of fiscal year 2025, Zhengye Biotechnology Holding Limited (ZYBT) had $7.2M in cash and equivalents against $1.4M in long-term debt.
What is Zhengye Biotechnology Holding Limited's gross margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a gross margin of 20.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zhengye Biotechnology Holding Limited's operating margin?
Zhengye Biotechnology Holding Limited (ZYBT) had an operating margin of -60.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Zhengye Biotechnology Holding Limited's net profit margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a net profit margin of -60.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Zhengye Biotechnology Holding Limited's return on equity (ROE)?
Zhengye Biotechnology Holding Limited (ZYBT) has a return on equity of -27.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Zhengye Biotechnology Holding Limited's free cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $1.8M in free cash flow during fiscal year 2025. This represents a -53.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zhengye Biotechnology Holding Limited's operating cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Zhengye Biotechnology Holding Limited's total assets?
Zhengye Biotechnology Holding Limited (ZYBT) had $62.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Zhengye Biotechnology Holding Limited's capital expenditures?
Zhengye Biotechnology Holding Limited (ZYBT) invested $144K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Zhengye Biotechnology Holding Limited spend on research and development?
Zhengye Biotechnology Holding Limited (ZYBT) invested $2.6M in research and development during fiscal year 2025.
What is Zhengye Biotechnology Holding Limited's current ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a current ratio of 1.14 as of fiscal year 2025, which is considered adequate.
What is Zhengye Biotechnology Holding Limited's debt-to-equity ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zhengye Biotechnology Holding Limited's return on assets (ROA)?
Zhengye Biotechnology Holding Limited (ZYBT) had a return on assets of -16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Zhengye Biotechnology Holding Limited's Piotroski F-Score?
Zhengye Biotechnology Holding Limited (ZYBT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zhengye Biotechnology Holding Limited's earnings high quality?
Zhengye Biotechnology Holding Limited (ZYBT) has an earnings quality ratio of -0.19x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Zhengye Biotechnology Holding Limited cover its interest payments?
Zhengye Biotechnology Holding Limited (ZYBT) has an interest coverage ratio of -20.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Zhengye Biotechnology Holding Limited?
Zhengye Biotechnology Holding Limited (ZYBT) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.